growing awareness and diagnosis of rare diseases are expected to boost the growth of the global plasma fractionation market at a CAGR of 4.28% during the forecast period 2025 to 2035

Plasma Fractionation Market to Grow at 6.59% CAGR, Driven by Demand for Immunoglobulin Therapies and Technological Advancements – Forecast till 2035

According to a detailed study by Market Research Future (MRFR), the Global Plasma Fractionation Market is projected to grow from USD 31.82 billion in 2024 to USD 64.22 billion by 2035, registering a CAGR of 6.59% during the forecast period (2025–2035). The market growth is primarily driven by the increasing demand for immunoglobulin therapies, advancements in fractionation technologies, and the rising prevalence of chronic and autoimmune diseases.

Key players operating in the global market include Octapharma, CSL Behring, Pfizer, Kedrion, Takeda Pharmaceutical, Grifols, and Baxter International, which are investing significantly in research, manufacturing expansion, and regulatory approvals to improve access to plasma-derived therapies, particularly in emerging and underserved regions.

Market Highlights

The Plasma Fractionation Market is experiencing steady growth, supported by an expanding patient population requiring immunoglobulin and coagulation factor therapies. The growing use of plasma-derived products in hematology, immunology, and general medicine continues to strengthen the industry outlook. Immunoglobulin remains the leading product type, with a valuation of USD 10.5 billion in 2024, expected to reach USD 18.0 billion by 2035. This rise reflects the growing adoption of plasma therapies to treat immune deficiencies and autoimmune conditions.

Furthermore, technological improvements in chromatography and filtration methods are enhancing yield efficiency and product purity, while rising awareness of the therapeutic benefits of plasma proteins is fostering demand across emerging regions.

Growing investment in healthcare infrastructure and favorable regulatory standards are also accelerating the market trajectory. The U.S., which allocates more than 10% of its GDP to healthcare, continues to lead global plasma therapy adoption. The combination of strong healthcare policies, production modernization, and increased clinical applications positions plasma fractionation as a key contributor to the global biopharmaceutical landscape.

Segment Analysis

The Plasma Fractionation Market is segmented by Application, Product Type, End User, and Technology.

The Global Plasma Fractionation Market is segmented by Application, Product Type, End User, and Technology.

By Application, the Plasma Fractionation Market is divided into Neurology, Hematology, General Medicine, and Immunology. Hematology and General Medicine dominate this segment, reflecting the extensive use of plasma-derived products in managing blood disorders and immune-related conditions. The Hematology segment is expected to grow from USD 6.8 billion in 2024 to USD 10.5 billion by 2035, driven by the increasing use of clotting factors in the treatment of hemophilia and other bleeding disorders.

By Product Type, the Plasma Fractionation Market is divided into Immunoglobulin, Albumin, Coagulation Factors, and Protease Inhibitors. Immunoglobulin dominates this category, accounting for the largest market share due to its vital role in treating immunodeficiencies and autoimmune conditions. Albumin follows as a critical therapeutic agent for fluid replacement and shock management, supported by high adoption in surgical and intensive care settings.

By End User, the Plasma Fractionation Market is divided into Hospitals, Ambulatory Surgical Centers, Blood Banks, and Pharmaceutical Companies. Hospitals hold the largest share as primary consumers of plasma-derived products for patient treatment and recovery. Ambulatory Surgical Centers are emerging as important users, focusing on outpatient therapies and minor surgical interventions that require plasma-based solutions. Blood Banks play a fundamental role in plasma collection and supply, ensuring an uninterrupted flow of raw materials for fractionation.

By Technology, the Plasma Fractionation Market is divided into Centrifugation, Chromatography, Precipitation, and Filtration. Centrifugation is widely used for efficient plasma component separation, making it a cornerstone technology in the fractionation process. Chromatography contributes significantly to enhancing product purity and recovery rates, particularly for immunoglobulins and albumin

Regional Analysis

The Global Plasma Fractionation Market is geographically segmented into North America, Europe, South America, Asia-Pacific, and the Middle East & Africa.

North America held the largest share, valued at USD 10.5 billion in 2024, and is projected to reach USD 16.5 billion by 2035, attributed to advanced healthcare systems and the high prevalence of chronic conditions. Europe follows closely, with a valuation of USD 6.5 billion in 2024, expected to reach USD 10.0 billion by 2035, driven by strong R&D activities and regulatory frameworks. Asia-Pacific, valued at USD 4.0 billion in 2024, is expected to expand to USD 6.5 billion by 2035, propelled by healthcare infrastructure development and growing patient awareness. South America and the Middle East & Africa are emerging markets, valued at USD 2.0 billion and USD 0.66 billion, respectively, in 2024, expected to grow to USD 6.5 billion and USD 1.5 billion by 2035, as awareness and healthcare access improve.

Key Findings of the Study

• The Global Plasma Fractionation Market was valued at USD 31.82 Billion in 2024 and is projected to reach USD 64.22 Billion by 2035, at a CAGR of 6.59% (2025–2035).• Immunoglobulin remains the dominant product segment, followed by Albumin and Coagulation Factors.• Hematology and General Medicine lead the application segments, supported by increasing demand for plasma-derived therapeutics.• North America holds the largest market share, while Asia-Pacific is the fastest-growing region.• Key players such as Octapharma, CSL Behring, Takeda, Baxter, and Grifols are expanding through R&D, facility investments, and strategic collaborations.• Advancements in plasma processing technologies and automation are improving yield efficiency and safety compliance.• Increasing prevalence of hemophilia, immunodeficiencies, and chronic disorders continues to drive global demand for plasma-derived products.

Related Report